Overcoming therapeutic inertia in patients with hypertension

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Uncontrolled blood pressure (BP) remains a leading contributor to cardiovascular disease and mortality worldwide. Although current practice guidelines recommend treating patients with hypertension to defined BP goals, the approach is not widely implemented, and BP control in clinical practice is much worse than that attained in clinical trials. Recent and ongoing clinical trials are utilizing more aggressive approaches with combination therapy as initial treatment. This article discusses the problem of therapeutic or clinical inertia when attempting to control hypertension and highlights differences in BP control rates between clinical trials and real-world practice. Additionally, the rationale for an ongoing treat-to-goal study using a fixed-dose combination of amlodipin/olmesartan medoxomil in patients with hypertension not controlled on monotherapy is provided.

Original languageEnglish (US)
Pages (from-to)118-124
Number of pages7
JournalPostgraduate Medicine
Volume122
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Blood Pressure
Hypertension
Pragmatic Clinical Trials
Clinical Trials
Therapeutics
Practice Guidelines
Cardiovascular Diseases
Mortality
Olmesartan Medoxomil

Keywords

  • BP goal
  • Combination therapy
  • Hypertension

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Overcoming therapeutic inertia in patients with hypertension. / Nesbitt, Shawna D.

In: Postgraduate Medicine, Vol. 122, No. 1, 01.2010, p. 118-124.

Research output: Contribution to journalArticle

@article{7d6fba4004d74d9aaeca9e16dd584cec,
title = "Overcoming therapeutic inertia in patients with hypertension",
abstract = "Uncontrolled blood pressure (BP) remains a leading contributor to cardiovascular disease and mortality worldwide. Although current practice guidelines recommend treating patients with hypertension to defined BP goals, the approach is not widely implemented, and BP control in clinical practice is much worse than that attained in clinical trials. Recent and ongoing clinical trials are utilizing more aggressive approaches with combination therapy as initial treatment. This article discusses the problem of therapeutic or clinical inertia when attempting to control hypertension and highlights differences in BP control rates between clinical trials and real-world practice. Additionally, the rationale for an ongoing treat-to-goal study using a fixed-dose combination of amlodipin/olmesartan medoxomil in patients with hypertension not controlled on monotherapy is provided.",
keywords = "BP goal, Combination therapy, Hypertension",
author = "Nesbitt, {Shawna D.}",
year = "2010",
month = "1",
doi = "10.3810/pgm.2010.01.2105",
language = "English (US)",
volume = "122",
pages = "118--124",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "1",

}

TY - JOUR

T1 - Overcoming therapeutic inertia in patients with hypertension

AU - Nesbitt, Shawna D.

PY - 2010/1

Y1 - 2010/1

N2 - Uncontrolled blood pressure (BP) remains a leading contributor to cardiovascular disease and mortality worldwide. Although current practice guidelines recommend treating patients with hypertension to defined BP goals, the approach is not widely implemented, and BP control in clinical practice is much worse than that attained in clinical trials. Recent and ongoing clinical trials are utilizing more aggressive approaches with combination therapy as initial treatment. This article discusses the problem of therapeutic or clinical inertia when attempting to control hypertension and highlights differences in BP control rates between clinical trials and real-world practice. Additionally, the rationale for an ongoing treat-to-goal study using a fixed-dose combination of amlodipin/olmesartan medoxomil in patients with hypertension not controlled on monotherapy is provided.

AB - Uncontrolled blood pressure (BP) remains a leading contributor to cardiovascular disease and mortality worldwide. Although current practice guidelines recommend treating patients with hypertension to defined BP goals, the approach is not widely implemented, and BP control in clinical practice is much worse than that attained in clinical trials. Recent and ongoing clinical trials are utilizing more aggressive approaches with combination therapy as initial treatment. This article discusses the problem of therapeutic or clinical inertia when attempting to control hypertension and highlights differences in BP control rates between clinical trials and real-world practice. Additionally, the rationale for an ongoing treat-to-goal study using a fixed-dose combination of amlodipin/olmesartan medoxomil in patients with hypertension not controlled on monotherapy is provided.

KW - BP goal

KW - Combination therapy

KW - Hypertension

UR - http://www.scopus.com/inward/record.url?scp=76249124887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76249124887&partnerID=8YFLogxK

U2 - 10.3810/pgm.2010.01.2105

DO - 10.3810/pgm.2010.01.2105

M3 - Article

C2 - 20107295

AN - SCOPUS:76249124887

VL - 122

SP - 118

EP - 124

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 1

ER -